drugset
drugset / Trial / NCT05333406

Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

NCT05333406 ↗

Phase 1 Completed 9 enrolled ENCell
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Charcot-Marie-Tooth disease (CMT) type 1A

Timeline

Start
2022-02-22
Primary completion
2022-12-20
Completion
2022-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject EN001 Cell therapy 500000 cells/kg Intravenous
Subject EN001 Cell therapy 2.5e+06 cells/kg Intravenous

Indications

Charcot-Marie-Tooth disease